Implanting the seeds
of medical innovation

From science
to life science

at Every Step

Medinol Group

Since 1992, our in-house research, development, and manufacturing have continuously raised the bar for revolutionary interventional cardiology products, constantly stretching the limits of innovation.

Structural Heart
structural heart 1
Valve Medical
Stenting and Catheterization
FV L04.2 MDL354422 Elunir2022 Update zeroBG
Implantable Microsensors
microsensor 1
Microtech Medical


Our pioneering cardiovascular intervention technology continues to demonstrate extraordinary clinical results, and our products constantly stretch the limits of medical science.


Ridaforolimus Eluting Coronary Stent System
Optimized stent deliverability and conformability with a metal spring tip.
Read More


Ridaforolimus Eluting Coronary Stent System
Redefining stent deliverability and visibility for fast and accurate implantation.
Read More

Product Pipeline

Our uncompromising devotion to clinical achievement powers the creation of our products, shapes our roadmap and drives the growth of our intellectual property portfolio.


Read More
Drug-eluting Hybrid Scaffold

Investigational device, restricted to investigational use only. Not available for sale.


Read More
Therapeutic Limus Delivery from an Unfracturable Stent

Investigational device, restricted to investigational use only. Not available for sale.
Revolutionizing TAVR With a Modular Device

Investigational device, restricted to investigational use only. Not available for sale.

Microtech Sensors

Read More
Sub-millimeter passive, implantable sensors

Investigational device, restricted to investigational use only. Not available for sale.

Medinol Group

At a Glance

Research & Development
The Medinol Group's R&D team is diverse and capable of supporting various knowledge areas including exotic metals, drugs, and polymers, as well as the development of unique medical device manufacturing equipment. Read More
Clinical Trials
The Medinol Group's Clinical Department conducts successful global clinical trials, advancing medicine and providing state-of-the-art treatments with commitment to patient safety. Read More
Quality Control & Regulatory Affairs
The Medinol's Quality Management System ensures our products meet the highest safety, efficacy, and reliability standards, using a risk-based approach to proactively address issues and continuously improve. Read More
The Medinol Group designs and manufactures high-quality stents using innovative techniques and materials to improve patient outcomes. Our expert team provides customized solutions that meet customer needs. Read More

Latest News

Latest News
August 18, 2023
Clinical considerations during spontaneous coronary artery dissection in the post-partum period: a case report*
Case summary: we report a case of a young women presenting with chest pain in the post-partum period. Her clinical appearance was that of a myocardial infarction, and angiography was indicative of a Type 2 SCAD. The patients had persistent chest pain, reduced left ventricular function, and critical left anterior descending artery stenosis. Percutaneous coronary intervention was done with caution.



Read More
June 8, 2023
TVT Conference - Valve Medical, First-in-Human TAVI Implant

Prof Eberhard Grube presented the successful FIH implantation of the XEMED TAVR device at the TVT 2023 Structural Heart Summit.


Read More
May 31, 2023
Valve Medical Announces Successful First-in-Human Implantation of Ultra-low Profile TAVR Valve in Israel

Valve Medical, a wholly owned subsidiary of Medinol Ltd. is pleased to announce today the successful First-in-Human (FIH) implantation of their advanced Transcatheter Aortic Valve Replacement (TAVR) system in Israel.

Read More
May 31, 2023
CTO Live Cases

We were proud to participate with our EluNIR DES System in the CTO Live Cases from 9 international centers with 26 expert interventional cardiologists on May 31st, 2023.

Read More
May 29, 2023
UP NEXT summit, Sourasky Medical

 Dr. Yoram Richter Medinol’s CEO joined a session on “Innovative stents and valves in cardiac disease” at the UP NEXT summit, Sourasky Medical Center (Ichilov), The first Israeli conference for technological innovation in healthcare.

Read More
May 25, 2023
Pavlodar City Cardio Center Conference

Our EluNIR DES System was presented last week at the Pavlodar City Cardio Center Conference, Kazakhstan, by our respected local distributor Dan Med LLP.

Read More
May 18, 2023
Medinol - PCR 2023

On PCR 2023, Prof. Maayan Konigstein, Director Interventional Cardiology Catheterization Unit, Tel Aviv Sourasky Medical Center – Ichilov in a lecture on: “The Medinol IoNir hybrid coronary DES system”.

Read More
May 5, 2020
Medinol Completes Enrollment of EluNIR-HBR Study

Medinol announces completion of enrollment in its EluNIR HIGH BLEEDING RISK (HBR) trial. A prospective, multi-center, single-arm, open-label post marketing clinical trial, to assess the safety and efficacy of the EluNIR Drug Eluting Stent (DES) in combination with shortened DAPT duration, in patients undergoing PCI who are considered to be at high bleeding risk.

Read More

Accessibility Toolbar